Apreo Health

Executive Summary

Apreo Health is a San Francisco-based digital health company founded in 2019, dedicated to developing safe and transformative solutions for lung disease. The company aims to restore patients' health and quality of life through innovative medical technology, leveraging digital tools to address respiratory conditions. While specific product details are not publicly available, Apreo Health's focus on pulmonary care aligns with a growing market need for non-invasive, connected health solutions that improve monitoring, diagnosis, and treatment adherence. The company operates in the early-stage private sector, with no disclosed funding rounds or valuation, suggesting it is still in the development or early commercialization phase. Given the competitive landscape in digital respiratory health, Apreo Health's success will depend on achieving clinical validation, regulatory clearance, and strategic partnerships. The company's ability to demonstrate efficacy through clinical trials and secure FDA approvals will be critical for adoption. With no known milestones or revenue, the risk profile is high, but the potential for impact in lung disease management—a leading cause of morbidity worldwide—is significant. Near-term catalysts include potential clinical data releases, regulatory designations, or funding rounds that could validate its technology and accelerate growth.

Upcoming Catalysts (preview)

• Q2 2027FDA Breakthrough Device Designation or 510(k) Clearance30% success
• Q4 2026Series A or Seed Funding Round Announcement50% success
• Q3 2027Clinical Study Results Published in Peer-Reviewed Journal25% success